Advances in gene therapy could revolutionize health care

...with a growing range of product launches anticipated.

PROJECTED CUMULATIVE GENE/CELL THERAPY PRODUCT LAUNCHES (2017 TO 2030)


Over 2,900 clinical trials using gene therapies are already underway or approved around the world.

The US undertook 67% of the 2,335 gene therapy clinical trials completed worldwide between 1989 and 2015.

Latest projections support around 500,000 US patients will have been treated with 40-60 products by 2030.

The advent of gene therapy could disrupt the healthcare industry as we know it, redefining the traditional avenues that pharmaceuticals and biotechnology make profits.

Over the past five years, biopharma’s approach to disease treatment has changed dramatically. Now, in the post human genome era, scientific advances have enabled us to develop techniques to target the root cause of disease – the genes that encode for these malfunctioning proteins. Collectively, we refer to these therapies as Gene Therapy (GTx). This technology is far more precise and powerful than in the past and, in some cases, it can offer close to curative treatments in a single dose.

While there has only been a few GTx approved by the US Food and Drug Administration (FDA) to date, the research into such therapies has rapidly expanded, as exemplified by the Investigational New Drug (IND) applications that are filed to test therapies in clinical trials. So far, most of these therapies target orphan monogenic diseases (diseases caused by a defect in a single gene). However, we believe that GTx will ultimately be used to treat far more prevalent conditions like heart failure, diabetes and even Alzheimer’s. The rapidly expanding addressable market, cutting-edge scientific techniques, and remarkable healthcare benefits GTx can provide make it a theme that we believe is ripe with potential opportunities.

*Amanda Birdsey-Benson, PhD, Director, Senior Research Analyst, Mellon*
All investments involve risk, including the possible loss of principal. Certain investments involve greater or unique risks that should be considered along with the objectives, fees, and expenses before investing.

Charts are provided for illustrative purposes and are not indicative of the past or future performance of any BNY Mellon Investment Management product.

BNY Mellon Investment Management is one of the world’s leading investment management organizations and one of the top U.S. wealth managers, encompassing BNY Mellon’s affiliated investment management firms, wealth management organization and global distribution companies. BNY Mellon is the corporate brand of The Bank of New York Mellon Corporation and may also be used as a generic term to reference the Corporation as a whole or its various subsidiaries generally.

Mellon is a global multi-specialist investment manager dedicated to serving our clients with a full spectrum of research-driven solutions. Mellon Investments Corporation (Mellon) is a registered investment adviser and an indirect subsidiary of The Bank of New York Mellon Corporation.

Views expressed are those of the manager stated and do not reflect views of the other managers or the firm overall. Views are current as of the date of this publication and subject to change. This information should not be construed as investment advice or recommendations for any particular investment. Please consult a legal, tax or investment advisor in order to determine whether an investment product or service is appropriate for a particular situation. No part of this material may be reproduced in any form, or referred to in any other publication, without express written permission. BNY Mellon Investment Management, Mellon and BNY Mellon Securities Corporation are subsidiaries of BNY Mellon.

Not FDIC-Insured | No Bank Guarantee | May Lose Value

MARK-78700-2019-09-23